Comparison of two different methods for the investigation of in vitro susceptibilities of planktonic and biofilm forming candida species to antifungal agents;Candida türlerinin biyofilm olu̧turan ve planktonik formlarinin antifungal ajanlara karşi in vitro duyarliliklarinin araç tirilmasinda iki farkli yöntemín kaŗilaştirilmasi

Mikrobiyoloji Bulteni

Volumn 44, Issue 4, 2010, Pages 619-631

  Kaynak Onurdač, Fatma ^a   Ozgen, Selda ^a   Abbasoǧlu, Ufuk ^a   Safa Gürcan, Ismail ^b  

^a GAZI UNIVERSITY   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

Antifungal agent; Biofilm; BioTimer assay; Calgary biofilm method; Candida; Planktonic; Susceptibility

Indexed keywords

ANTIFUNGAL AGENT;

ARTICLE; BIOFILM; CANDIDA; COMPARATIVE STUDY; DRUG EFFECT; HUMAN; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; PHYSIOLOGY; PLANKTON;

ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA; HUMANS; MICROBIAL SENSITIVITY TESTS; PLANKTON;

EID: 78649247436     PISSN: 03749096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing yeast. Approved Standard, M27-A3. 2008. CLSI, Wayne, Pa.
2. Shuford JA, Piper KE, Steckelberg JM, Patel R. In-vitro characterization and activity of antifungal agents alone and in combination against sessile and planktonic clinical Candida albicans isolates. Diagn Microbiol Infect Dis 2007; 57: 277-81.
3. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial blood stream infections in US hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-17.
4. Pace JL, Rupp ME, Finch RG. Biofilms, Infection and Antimicrobial Therapy, pp.171-84. In: Hawser S, Islam K (eds), Candida. 2006. Taylor and Francis Group, Boca Raton.
5. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002; 46: 1773-80.
6. Ramage G, Walle K, Wickes B, Lopez-Ribot J. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob Agents Chemother 2001; 45: 2475-9.
7. Gilbert P, Das J, Foley I. Biofilm susceptibility to antimicrobials. Adv Dent Res 1997; 11: 160-7.
8. Smith AW. Biofilms and antibiotic therapy: is there a role for combating bacterial resistance by the use of novel drug delivery systems? Adv Drug Deliv Rev 2005; 57: 1539-50.
9. Balaban N, Ren D, Givskov M, Rasmussen TB. Introduction, pp: 1-12. In: Balaban N (ed), Control of Biofilm Infections By Signal Manipulation. 2008. Springer, Berlin.
10. Cengiz SA, Us E, Cengiz AT. Slime faktörünün klinikteki yen ve önemi. Inönü Üni Tip Fak Derg 2006; 13: 193-7.
11. Pantanella F, Valenti P, Frioni A, Natalizi T. Biotimer assay, a new method for counting Staphylococcus spp. in biofilm without sample manipulation applied to evaluate antibiotic susceptibility of biofilm. J Microbiol Methods 2008; 75: 478-84.
12. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 1999; 37: 1771-6.
13. Olson ME, Ceri H, Morck DW, Buret AG, Read RR. Biofilm bacteria: formation and comparative susceptibility to antibiotics. Can J Vet Res 2002; 66: 86-92.
14. Clutterbuck AL, Cochrane CA, Dolman J, Percival SL. Evaluating antibiotics for use a medicine using a poloxamer biofilm model. Ann Clin Microbiol Antimicrob 2007; 15: 6-12.
15. Moskowitz SM, Foster JM, Emerson J, Burns JL. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cyctic fibrosis. J Clin Microbiol 2004; 42: 1915-22.
16. Pettit RK, Weber CA, Kean MJ, et al. Microplate Alamar blue assay for Staphylococcus epidermidis biofilm susceptibility testing. Antimicrob Agents Chemother 2005; 49: 2612-7.
17. Özkan S, Kaynak F, Kalkanci A, Abbasoglu U, Kuştimur S. Slime production and proteinase activity of Candida species isolated from blood samples and the comparison of these activites with minimum inhibitory concentration values of antifungal agents. Mem Inst Oswaldo Cruz 2005; 100: 319-24.
18. Özkan S, Kaynak F, Abbasoǧlu U, Gür D. The susceptibility of Candida strains isolated from pediatric patients to various antifungal agents. Turk Mikrobiyol Cem Derg 2004; 34: 253-6.
19. Abdi-Ali A, Mohammadi-Mehr M, Agha Alaei Y. Bactericidal activity of various antibiotics against biofilmproducing Pseudomonas aeruginosa. Int J Antimicrob Agents 2006; 27: 196-200.
20. Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, Ghannoum MA. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J Bacteriol 2001; 183: 5385-94.
21. Serefko A, Chudzik B, Malm A. In vitro activity of caspofungin against planktonic and sessile Candida spp. cells. Polish J Microbiol 2006; 55: 133-7.
22. Jain N, Kohli R, Cook E, Gialanella P, Chang T, Fries BC. Biofilm formation by and antifungal susceptibility of Candida isolates from urine. Appl Environ Microbiol 2007; 73: 1697-703.
23. Hawser SP, Douglas LJ. Biofilm formation by Candida species on the surface of catheter materials in vitro. Infect Immun 1994; 62: 915-21.